Or register here

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

key information

source: The New England Journal of Medicine

year: 2016

authors: Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC

summary/abstract:

BACKGROUND:
Sickle cell anemia is an inherited blood disorder that is characterized by painful vaso-occlusive crises, for which there are few treatment options. Platelets mediate intercellular adhesion and thrombosis during vaso-occlusion in sickle cell anemia, which suggests a role for antiplatelet agents in modifying disease events.
METHODS:
Children and adolescents 2 through 17 years of age with sickle cell anemia were randomly assigned to receive oral prasugrel or placebo for 9 to 24 months. The primary end point was the rate of vaso-occlusive crisis, a composite of painful crisis or acute chest syndrome. The secondary end points were the rate of sickle cell-related pain and the intensity of pain, which were assessed daily with the use of pain diaries.
RESULTS:
A total of 341 patients underwent randomization at 51 sites in 13 countries across the Americas, Europe, Asia, and Africa. The rate of vaso-occlusive crisis events per person-year was 2.30 in the prasugrel group and 2.77 in the placebo group (rate ratio, 0.83; 95% confidence interval, 0.66 to 1.05; P=0.12). There were no significant differences between the groups in the secondary end points of diary-reported events. The safety end points, including the frequency of bleeding events requiring medical intervention, of hemorrhagic and nonhemorrhagic adverse events that occurred while patients were taking prasugrel or placebo, and of discontinuations due to prasugrel or placebo, did not differ significantly between the groups.
CONCLUSIONS:
Among children and adolescents with sickle cell anemia, the rate of vaso-occlusive crisis was not significantly lower among those who received prasugrel than among those who received placebo. There were no significant between-group differences in the safety findings. (Funded by Daiichi Sankyo and Eli Lilly; ClinicalTrials.gov number, NCT01794000.).

organization: Boston Children's Cancer and Blood Disorders Center; UCSF Benioff Children's Hospital Oakland; American University of Beirut; Evelina Children's Hospital (B.I.), Guy's and St. Thomas' Hospital (B.I.), Daiichi Sankyo Development (D.Z.), and King's College Hospital, Denmark Hil; Medical University of South Carolina; Kenya Medical Research Institute; Eli Lilly, Indianapolis; Korle Bu Teaching Hospital, Accra; Azienda Ospedaliera-University of Padua; Alexandria University; Centre Hospitalier Universitaire Sainte-Justine

DOI: 10.1056/NEJMoa1512021

read more full text

Log in

Enter the code

Join the community

Trusted Resources Home

Education & Research

People & Places

News & Events

Videos & Visuals

Community Center

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

Related Content

Powered by

Log in

Enter Phone Number

Enter the code

Join the community

Trusted Resources Home

Education & Research

People & Places

News & Events

Videos & Visuals

Community Center

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

Related Content

Powered by

Support for this site is provided by